Company reviews through a translational science lens.

Reviews written by group members on companies whose work aligns with our group's research focus. We seek to highlight innovations, challenges, and the potential impact of these technologies on the field.

Reviews

Industry perspectives from the DeSimone Research Group

A visual feed for evaluating platforms adjacent to bioprinting, drug delivery, and translational manufacturing.

June 6, 2025

FluidForm Bio

Fluidform Bio is an early-stage biotech company specializing in 3D bioprinting of living human tissues using its proprietary FRESH™ platform. Spun out of Carnegie Mellon University in 2018, the company leverages a thermoreversible gelatin microparticle support matrix to print delicate biological structures with high resolution and native-like function. The enhanced FRESH v2.0 system enables direct printing of unmodified hydrogels and dense, cell-laden bioinks, overcoming key challenges in soft tissue fabrication.

Read the full review

April 10, 2025

RenovoRx, Inc.

RenovoRx is a clinical-stage biopharmaceutical company developing targeted intra-arterial (IA) drug delivery for solid tumors, with a focus on improving precision oncology and reducing systemic toxicity. Their proprietary TAMP™ platform, delivered via the RenovoCath® dual-balloon catheter, enables localized chemotherapy infusion directly into tumor-adjacent arteries. The company's lead product, RenovoGem™, is being evaluated in the Phase 3 TIGeR-PaC trial for pancreatic cancer, showing promising survival benefits, especially in patients with prior chemoradiation. While early studies support the feasibility and reduced systemic exposure of this approach, procedural risks such as arterial thrombosis and vessel injury remain concerns. RenovoRx continues to explore its platform in other cancers, with ongoing trials shaping its potential clinical impact.

Read the full review

Section 01

Lab Startups

Innovations emerging from our research have launched startup companies that advance lab-developed technologies toward practical applications and broader impact.

PinPrint

Our innovations in 3D-printed microneedle array patches led to the founding of PinPrint, translating research from the lab into technologies for minimally invasive drug and vaccine delivery and interstitial fluid sampling.